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Clinics and pathology 
Disease 
Acute megakaryoblastic leukemia (AML -M7) 
Note 
Acute megakaryoblastic leukemia (AMKL) was so far 
divided into three subgroups: AMKL arising in patients 
with Down syndrome (DS-AMKL), AMKL with a 
t(1;22)(p13;q13) giving rise of a 5' OTT - 3' MAL 
fusion gene, and "other" AMLKs, non Down syndrome 
/ non t(1;22). 
Two new categories have recently been individualized 
from the subgroup "non Down syndrome / non t(1;22)": 
the inv(16)(p13q24) CBFA2T3/GLIS2, and the 
t(11;12)(p15;p13) NUP98/KDM5A (Gruber et al., 
2012; Thiollier et al., 2012).  
This t(11;12)(p15;p13) has been described earlier in a
single case (van Zutven et al., 2006). 
Epidemiology 
From the two recent studies, t(11;12)(p15;p13) 
NUP98/KDM5A was found in about 10% of pediatric 
acute megakaryoblastic leukemia, excluding AMLKs 
occuring in Down syndrome patients; NUP98/KDM5A 
was detected in 8% (4 of 48) of pediatric cases.  
This chimeric transcript was not detected in adult 
AMKLs (Gruber et al., 2012). From another validation 
cohort of 22 non-DS pediatric AMKL, 9  
DS AMKL, and 8 adult AMKL, a NUP98/KDM5A 
fusion was characterized in two patients (Thiollier et 
al., 2012). 
Clinics 
7 cases to date; data on age and sex are available in 5 
cases (van Zutven et al., 2006; Gruber et al., 2012): 
there was 5 boys and no girl; sex ratio, so far, appe rs 
to be highly unbalanced, although the sample is very 
small; median age was 1 year 4 months (range: 1 year - 
4 years). 
Prognosis 
Prognostic data available in only one case (van Zutven 
et al., 2006): the patient remained in complete 
remission for at least 5 years. 
Cytogenetics 
Cytogenetics morphological 
Not visible with conventional banding techniques 
alone: misdiagnosed as add(11)(p15) and 
der(21)(t(11;21)(p15;p13), and chromosome 12 was 
cytogenetically normal by conventional banding 
techniques and only identified as a partner in this 
translocation after FISH in the first reported case (van 
Zutven et al., 2006).  
A complex karyotype was found in 4 of the 5 cases 
with data on chromosomes; the remaining case 
exhibited an apparently normal karyotype (van Zutven 
et al., 2006; Gruber et al., 2012). 
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Schematic representation of the fusion NUP98-KDM5A (previously named NUP98-JARID1A). From up to down: NUP98, JARID1A 
and the putative chimeric NUP98-JARID1A structure. FG-repeats: phenylalanine-glycine repeats; JMJ: Jumonji domains; ARID: AT-rich 
interaction domain; PHD: plant homeodomain fingers or LAP domains. The arrow indicates the position of the fusion (Laura JCM van 
Zutven and H Berna Beverloo). 
 





920 amino acids; 97 kDa; contains repeated motifs 
(GLFG and FG) in N-term and a RNA binding motif in 
C-term.  
Nucleoporin: associated with the nuclear pore complex; 





The gene was previously known as JARID1A. 
Protein 
1722 amino acids; 196 kD; retinoblastoma binding 
protein 2. Lysine-specific histone 3 demethylase; 
involved in chromatin-regulation; can function as a 
transcriptional repressor. KDM5A-mediated histone H3 
lysine 4 demethylation contributes to silencing of 
retinoblastoma target genes (Chicas et al., 2012). 
Dysregulation of KDM5A is associated with various 
human cancers: gastric cancer, lung cancer, breast 
cancer (Hou et al., 2012). 




In-frame fusion of the first 13 exons of NUP98 to 
exons 28-31 of KDM5A. 
Transcript 
5' NUP98 - 3' KDM5A. 
Detection 
FISH: BAC clones RP11-348A20 (NUP98) and RP11-
283I3 (spanning KDM5A exon 11-31) colocalize. 
Fusion protein 
Description 
The NUP98/KDM5A fusion protein contains the Phe-
Gly (FG) repeats of the N-terminal part of NUP98. The 
KDM5A (JARID1A) sequence starting with exon 28 
still contains the sequence encoding the C-terminal 
PHD domain. 
Oncogenesis 
Results in deregulation of HOXA genes through 
recruitment of the histone acetyltransferase CBP/p300 
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